ClinicalTrials.gg
RecruitingNCT07528027Updated Sep 24, 2026

Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity

A Phase 3 interventional study of HRS-7535 and Placebo in Hypertension With Overweight or Obesity, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
648
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 13 under way, 4 of them phase 3. Obesity · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
Largest of 24
648 · median 130
Started
2026
with 6 others
Phase 3
6 of 24
2 open now
Primary completion
2027-12
later than 12 of 12 live
Registered
20th of 24
by date

Among the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., this one has the largest planned enrollment, is one of 7 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 12 of the 12 other live ones, and was the 20th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;

03

Conditions studied

  • Hypertension With Overweight or Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. On the day of signing the form, the age should be between 18 and 70 years old, with no gender restrictions;
  2. When screening and randomizing, the average office blood pressure meets any of the following conditions: ① 140 mmHg ≤ SBP \< 170 mmHg, and DBP \< 110 mmHg; ② 90 mmHg ≤ DBP \< 110 mmHg, and 130 mmHg ≤ SBP \< 170 mmHg;
  3. Patients with untreated hypertension, or those who have received stable doses of any or all of the following classes of antihypertensive medications within 30 days prior to screening: 1) angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), 2) thiazides and thiazide-like diuretics, 3) calcium channel blockers. Patients who are currently receiving stable doses of beta blockers (such as metoprolol or atenolol) or mineralocorticoid receptor antagonists (such as spironolactone) and intend to continue these treatments at their current doses may be included in this study;
  4. During screening, should be ≥24 kg/m2;

Exclusion criteria

Exclusion Criteria:

  1. Having a known secondary cause of hypertension
  2. History of previously diagnosed heart failure with reduced (HFrEF);
  3. Those who have undergone coronary revascularization within the previous 90 days or plan to undergo it during the trial period;
  4. Diagnosed or suspected with type 1 diabetes, special type of diabetes, or secondary diabetes (excluding gestational diabetes);
  5. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/requiring treatment of gallbladder disease (excluding those who have undergone cholecystectomy but are still eligible for enrollment as determined by the investigator);
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
648 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS-7535

    Drug: HRS-7535

  • Placebo comparator
    Treatment group B: Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in SBP relative to baseline at Week 24

    Time frame: at Week 24

Secondary outcomes

  1. Changes in SBP during 24-hour ambulatory blood pressure monitoring (ABPM) at Week 24 and Week 48;

    Time frame: at Week 24 and Week 48;

  2. Percentage of weight change at Week 24 and 48

    Time frame: at Week 24 and 48

  3. The changes in blood lipid at Week 24 and 48;

    Time frame: at Week 24 and 48;

07

Study locations

2 of 2 sites recruiting
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
    Recruiting
    • Jianping Li · Principal investigator
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 163711, China
    Recruiting
    • Yue Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartActual
May 29, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jan 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07528027
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 29, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Pengfei Wang
Contact
pengfei.wang.pw5@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safiglipron

Start the discussion